a Hospital Universitario Dr. José Eleuterio González y Facultad de Medicina, Servicio de Gastroenterología,Nuevo León , Universidad Autónoma de Nuevo León , Monterrey , México.
Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):819-827. doi: 10.1080/17474124.2018.1496017. Epub 2018 Jul 13.
Helicobacter pylori is a Gram-negative bacterium that causes chronic gastritis, dyspepsia, peptic ulcers, and gastric cancer. Over half the world's population is infected with H. pylori, with higher prevalence in developing countries. Areas covered: In this review, current guidelines on H. pylori therapy, such as the Toronto consensus statement, the Maastricht V/Florence consensus report, and the American College of Gastroenterology guidelines, are compared. Also, we analyzed reports of antimicrobial resistance of H. pylori published in PubMed in the last years to determine current antimicrobial resistance worldwide. Expert commentary: Although H. pylori antimicrobial resistance varies by geographic area, its prevalence has been increasing over time, causing therapy failures and low eradication rates. To best optimize the management of H. pylori infection, H. pylori therapy should be based on patterns of local and individual antimicrobial resistance, if possible.
幽门螺杆菌是一种革兰氏阴性细菌，可导致慢性胃炎、消化不良、消化性溃疡和胃癌。超过一半的世界人口感染了幽门螺杆菌，发展中国家的感染率更高。涵盖领域：在这篇综述中，比较了当前关于幽门螺杆菌治疗的指南，如多伦多共识声明、马斯特里赫特 V/佛罗伦萨共识报告和美国胃肠病学会指南。此外，我们还分析了过去几年在 PubMed 上发表的关于幽门螺杆菌抗药性的报告，以确定全球目前的抗药性情况。专家评论：尽管幽门螺杆菌的抗药性因地理区域而异，但随着时间的推移，其流行率一直在上升，导致治疗失败和低根除率。为了最好地优化幽门螺杆菌感染的管理，如果可能的话，幽门螺杆菌的治疗应该基于当地和个体的抗药性模式。
